HRPC(SH:600829)2022-04-20 16:00Financial Performance - The company's operating revenue for Q1 2022 was CNY 2,328,665,371.67, representing a year-on-year increase of 7.70%[4] - The net profit attributable to shareholders for the same period was CNY 46,129,003.55, reflecting a growth of 15.28% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 45,267,744.20, which is an increase of 19.16% year-on-year[4] - The basic earnings per share for Q1 2022 was CNY 0.0795, up by 15.22% from the same period last year[4] - The net profit for Q1 2022 was CNY 46,087,379.78, an increase of 15.6% compared to CNY 39,850,517.98 in Q1 2021[27] - The operating profit for Q1 2022 reached CNY 62,632,567.52, up from CNY 54,991,628.74 in the same period last year, reflecting a growth of 13.0%[27] - The basic and diluted earnings per share for Q1 2022 were both CNY 0.0795, up from CNY 0.0690 in Q1 2021, marking a growth of 7.2%[28] - The total tax expenses for Q1 2022 amounted to CNY 16,599,926.62, compared to CNY 15,164,278.34 in Q1 2021, reflecting an increase of 9.4%[27] Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,704,745,514.97, a decrease of 0.64% from the end of the previous year[6] - Total assets as of March 31, 2022, were CNY 6,704,745,514.97, slightly down from CNY 6,747,990,176.18 at the end of 2021[25] - Total liabilities decreased to CNY 4,459,430,352.42 from CNY 4,548,762,393.41 at the end of 2021, a decline of 2.0%[25] - Total liabilities as of March 31, 2022, were CNY 101,196,815.62, a minor decrease from CNY 101,219,998.76 as of December 31, 2021[37] - Total equity as of March 31, 2022, was CNY 1,684,045,453.35, compared to CNY 1,683,342,954.08 as of December 31, 2021[37] Cash Flow - The company reported a negative net cash flow from operating activities of CNY -39,018,919.18, which is not applicable for year-on-year comparison[4] - The cash flow from operating activities showed a net outflow of CNY -39,018,919.18, an improvement from CNY -268,587,146.78 in Q1 2021[31] - Cash and cash equivalents as of March 31, 2022, amounted to CNY 778,777,950.28, a decrease of 2.9% from CNY 800,491,645.34 at the end of 2021[23] - Cash and cash equivalents at the end of Q1 2022 were CNY 778,777,950.28, compared to CNY 375,010,925.25 at the end of Q1 2021, representing an increase of 107.5%[33] - The cash inflow from financing activities was CNY 420,000,000.00, down from CNY 710,974,027.78 in Q1 2021, indicating a decrease of 41.0%[33] - The cash outflow for investing activities was CNY 278,841.32, significantly lower than CNY 931,647.85 in Q1 2021, showing a decrease of 70.0%[31] Operational Challenges - The company faced challenges due to national medical reform policies leading to a decrease in drug prices, which compressed profit margins[7] - The company continues to adapt its operations in response to the ongoing COVID-19 pandemic, ensuring stable business development despite challenges[18] - Ongoing litigation regarding a construction contract may impact future profits, but the outcome remains uncertain[19] Receivables and Inventory - Accounts receivable increased to CNY 4,093,130,493.93 as of March 31, 2022, compared to CNY 3,852,043,406.77 at the end of 2021, representing a growth of 6.3%[23] - Inventory decreased to CNY 928,793,612.90 from CNY 1,105,348,382.06 at the end of 2021, indicating a reduction of 16.0%[23] Business Strategy - The company has strengthened its wholesale business by deepening cooperation with medical institutions and expanding its terminal market[7] - The company actively collected receivables and managed cash flow, resulting in a net cash flow from operating activities that improved compared to the same period last year[7] Research and Development - Research and development expenses were not explicitly detailed but are part of the overall management expenses of CNY 389,050.95 for Q1 2022[40]